Platelet-derived growth factor receptor A (PDGFRA) mutations occur in approximately 10–
15% of gastrointestinal stromal tumors (GISTs). These tumors with PDGFRA mutations have …

The tyrosine kinase inhibitor (TKI) imatinib has radically changed the natural history of KIT-
driven gastrointestinal stromal tumours (GISTs). Approved second-line and third-line …

Gastrointestinal stromal tumors (GIST) are the most common type of soft tissue sarcoma that
occur throughout the gastrointestinal tract. Most of these tumors are caused by oncogenic …

Background Gastrointestinal stromal tumours (GIST) are the most common mesenchymal
neoplasms of the gastrointestinal tract. Imatinib followed by sunitinib and regorafenib is the …

Background This investigator-initiated trial provided the justification for the phase III GRID
study resulting in worldwide regulatory approval of regorafenib as a third-line therapy for …

Gastrointestinal stromal tumors (GIST) are the most common soft tissue sarcoma of the
gastrointestinal tract, resulting most commonly from KIT or platelet-derived growth factor …

Background: This multicentre phase II trial (DOVIGIST) evaluated the antitumour activity of
dovitinib as second-line treatment of patients with gastrointestinal stromal tumour (GIST) …

Introduction: Discovery of oncogenic mutations in the KIT and PDGFRA tyrosine kinase
receptor was a crucial step for the development of tyrosine kinase inhibitors (TKIs). Since …

Gastrointestinal stromal tumors (GISTs) are the most common malignant mesenchymal
neoplasms of the gastrointestinal tract. The gold standard for the diagnosis of GISTs is …

Activating mutations in KIT/PDGFRA receptor tyrosine kinases drive gastrointestinal stromal
tumors (GIST). KIT/PDGFRA inhibitors, such as imatinib do not evoke an effective cytocidal …